Sophie C. McGrath

• Advised Achilles Therapeutics, a biopharmaceutical company developing personalised cancer immunotherapies, on the completion of its £52.7 million Series C. 
• Advised COMPASS Pathways plc on its $146.6 million initial public offering on NASDAQ, and its $80 million crossover round. Compass is a life sciences company dedicated to accelerating patient access to evidence based innovation in mental health.
• Advised Arix Bioscience Holdings Limited, a global venture capital company focused on investing in and building breakthrough biotech companies, on the completion of its €1.5 million investment into Twelve Bio ApS as part of its €4 million seed round. 
• Advised Morningside Ventures, and early stage venture investor, on the completion of its £23.7 million investment into Immune Regulation Limited as part of a £40.6 million Series B funding round.
• Advised a deep tech bio company on the completion of its London-seed round.
• Advised Rockend Limited, a company aiming to create novel treatment methods by developing and utilizing engineered platelets for the delivery of therapeutic agents, on its £4.5 million seed financing.
• Advised Novo Holdings A/S, a leading international life sciences investor, on its $40 million investment as part of a $60 million Series C funding round into Exscientia Limited, a world leading AI-driven drug discovery company based in the UK.
• Advised Achilles Therapeutics, a biopharmaceutical company developing personalised cancer immunotherapies, on the completion of its £100 million Series B crossover round, which was one of the largest growth stage venture rounds for a UK biotech company in 2019.
• Advised Coöperatieve Gilde Healthcare IV U.A., a specialised European healthcare-focused investment fund based in the Netherlands, on its $10 million investment in Big Health Ltd as part of a $25 million Series B.Big Health’s purpose is to help millions back to good mental health, with digital therapeutics - fully automated and highly personalised behavioural programs for mental health.
• Advised Advanced Medical Solutions Group plc, an AIM listed life sciences company, on its acquisition of Sealantis Limited, a developer of an alginate-based tissue adhesive technology platform.
• Advised QuantaDialysis Technologies Limited, a medical device company focused on haemodialysis systems for use in the clinic and home, on its Series C funding round raising over £38 million.
• Advised Brytlyt Limited, a company that is developing and commercializing GPU-accelerated data processing technology, on its Series A funding round.
• Advised Wintermute Trading Limited, a leading global algorithmic market maker in cryptocurrency markets, on its $2.8 million Series A.
• Advised Joanna Dai Limited, a luxury performance workwear brand specializing in sustainable, versatile and high-tech women’s workwear, on its seed funding round.
• Advised med24 Limited, a new provider of private medical clinics and virtual services for 24/7 immediate access healthcare in London, on its £5 million seed financing.
• Advised Advent Life Sciences, a leading trans-Atlantic venture investors focused on building innovative Life Sciences businesses in the UK, Europe and the USA, on its £4 million Series A investment into Amphista Therapeutics.
• Advised Cognitive Credit, a company developing an end-to-end analytics application that delivers cutting edge technology to institutional credit investors, on its convertible loan from the Future Fund and existing investors.
• Advised Beyond.Life Ltd, providing an online marketplace that connects funeral directors and at-need customers, on its Series A round.
• Advised Novastar Ventures Limited, an impact investment fund, on its Series A investment in The Sure Chill Company Limited, a company that develops a revolutionary platform cooling technology.
• Advised N+1 Singer as nominated adviser and broker to Verona Pharma plc, a listed drug development company, in relation to its £44.7 million UK and U.S. placing.*
• Advised a listed life sciences company in relation to its acquisition of a medical devices business based in the U.S.*
• Advised Neuroprotexeon Limited, a late clinical-stage pharmaceutical and medical device company, on its initial spinout from Imperial College London, subsequent rounds of private financing and issues relating to the cross border nature of its operations.*
• Advised Gilde Healthcare Partners B.V. as lead investor on multiple financing rounds into Lumeon Limited, a digital healthcare company.*
• Advised Novo A/S, Lundbeckfond A/S and Gilde Healthcare Partners B.V. on multiple financing rounds into Acacia Pharma Limited and in relation to its ultimate listing on Euronext. Acacia Limited is a specialty pharmaceutical company focused on the development and commercialisation of new treatments for the conditions arising as a consequence of surgery, cancer or cancer treatment.*
• Advised Arc Medical Limited, a UK medical devices company, on a partial exit by certain shareholders to Norgine Ventures, along with a strategic investment and working capital facility from Norgine.*
  • Advised Cruncher Technologies Limited, a company using artificial intelligence to solve big data issues for the financial markets, on various financing rounds and its commercialisation into the U.S.*
• Advised EQ Investors, a B Corporation certified wealth manager (B Corporations are for-profit companies certified as meeting rigorous standards of social and environmental performance, accountability, and transparency), in relation to the acquisition of Truestone Wealth Management, a financial planning firm with £500 million of client assets under management.*
• Advised Mustard Seed, an impact investment fund, on multiple investments including:*
  • Skin Healthcare, a skin analytics app and device designed to help identify early signs of skin cancer.
  • Beulah, a luxury goods company providing employment opportunities to victims of human trafficking.
  • Switchee, a company seeking to significantly reduce energy use and spending.

* Denotes experience prior to joining Goodwin.